Rohan Thomas E, Arthur Rhonda, Wang Yihong, Weinmann Sheila, Ginsberg Mindy, Loi Sherene, Salgado Roberto
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, 1300 Morris Park Ave., Bronx, NY, 10461, USA.
Department of Pathology and Laboratory Medicine, Rhode Island Hospital and Lifespan Medical Center, Warren Alpert Medical School of Brown University, Providence, RI, 02903, USA.
Breast Cancer Res. 2021 Jan 30;23(1):15. doi: 10.1186/s13058-021-01395-x.
It is well established that tumors are antigenic and can induce an immune response by the host, entailing lymphocytic infiltration of the tumor and surrounding stroma. The extent and composition of the immune response to the tumor, assessed through evaluation of tumor-infiltrating lymphocyte counts, has been shown in many studies to have prognostic and predictive value for invasive breast cancer, but currently, there is little evidence regarding the association between infiltrating immune cell counts (IICCs) in women with benign breast disease (BBD) and risk of subsequent invasive breast cancer.
Using a cohort of 15,395 women biopsied for BBD at Kaiser Permanente Northwest, we conducted a nested case-control study in which cases were women who developed a subsequent invasive breast cancer during follow-up and controls were individually matched to cases on age at BBD diagnosis. We assessed IICCs in normal tissue and in the BBD lesions, and we used unconditional logistic regression to estimate the multivariable odds ratios (OR) and 95% confidence intervals (CI) for the associations between IICCs and breast cancer risk.
There was no association between the IICC in normal tissue (multivariable OR per 5% increase in IICC = 1.05, 95% CI = 0.96-1.16) or in the BBD lesion (OR per 5% increase in IICC = 1.06, 95% CI = 0.96-1.18) and risk of subsequent invasive breast cancer. Also, there were no associations within subgroups defined by menopausal status, BBD histology, BMI, and history of smoking.
The results of this study suggest that IICCs in BBD tissue are not associated with altered risk of subsequent invasive breast cancer.
肿瘤具有抗原性，可诱导宿主产生免疫反应，导致肿瘤及周围基质出现淋巴细胞浸润，这一点已得到充分证实。通过评估肿瘤浸润淋巴细胞计数来评估对肿瘤的免疫反应程度和组成，在许多研究中已显示其对浸润性乳腺癌具有预后和预测价值，但目前，关于患有乳腺良性疾病（BBD）的女性中浸润性免疫细胞计数（IICC）与后续浸润性乳腺癌风险之间的关联，证据很少。
我们利用在西北凯撒永久医疗中心接受BBD活检的15395名女性队列进行了一项巢式病例对照研究，其中病例为随访期间发生后续浸润性乳腺癌的女性，对照则根据BBD诊断时的年龄与病例进行个体匹配。我们评估了正常组织和BBD病变中的IICC，并使用无条件逻辑回归来估计IICC与乳腺癌风险之间关联的多变量比值比（OR）和95%置信区间（CI）。
正常组织中的IICC（IICC每增加5%的多变量OR = 1.05，95% CI = 0.96 - 1.16）或BBD病变中的IICC（IICC每增加5%的OR = 1.06，95% CI = 0.96 - 1.18）与后续浸润性乳腺癌风险之间均无关联。此外，在按绝经状态、BBD组织学、BMI和吸烟史定义的亚组中也无关联。
本研究结果表明，BBD组织中的IICC与后续浸润性乳腺癌风险改变无关。
